MindWalk Holdings Corp

Today's Performance

Last

$1.13

% Chg

-5.83%

High

1.21

Volume

536

Open

1.16

Low

1.10

$ Chg

-0.07

Prev. Close

1.20

After Hours

Price

$1.13

Volume

536

Change

-0.07

% Chg

-5.83%

Daily Short vs Long Volume

Short Volume

1.03m shares (192,763.81%)

Long Volume

-1.03m shares (-192,663.81%)

Short Interest: 1.03m shares (2.42% of free float)

Dividend

Ex-Div Date

unavailable

Yield

Div. Freq.

Div. Pay Date

unavailable

Share Information

Year High

unavailable

Shares Out

47.57m

PE Ratio

unavailable

Year Low

unavailable

Marketcap

53.76m

PB Ratio

7.53

Exchange

NASDAQ

EPS

-0.32

LATEST PRESS RELEASE

Oct 26, 2026

A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets

Oct 22, 2026

MindWalk Holdings Corp. Announces Leadership Update

Oct 21, 2026

AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.

Oct 21, 2026

MindWalk Screens 890,634 Antibody Sequences for Immune Risk in Under Five Hours

Oct 14, 2026

AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

Oct 14, 2026

MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies

Oct 06, 2026

Drug Discovery Informatics Market Projected to Reach $7.74 Billion by 2030 as AI Agents Need Biological Context

Oct 06, 2026

MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function

Oct 01, 2026

AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment

Oct 01, 2026

$1.13

LATEST PRESS RELEASE

A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets

MindWalk Holdings Corp. Announces Leadership Update

AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.

MindWalk Screens 890,634 Antibody Sequences for Immune Risk in Under Five Hours

AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies

Drug Discovery Informatics Market Projected to Reach $7.74 Billion by 2030 as AI Agents Need Biological Context

MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function

AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment

MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director

Subscribe for updates on HYFT